Cargando…

High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction

SIMPLE SUMMARY: Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). We examined the relationship between the trough plasma concentrations of afatinib and adverse effects,...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Takayuki, Terazono, Hideyuki, Suetsugu, Takayuki, Sugawara, Hideki, Arima, Junko, Nitta, Mina, Tanabe, Toru, Okutsu, Kayu, Ikeda, Ryuji, Mizuno, Keiko, Inoue, Hiromasa, Takeda, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305619/
https://www.ncbi.nlm.nih.gov/pubmed/34298637
http://dx.doi.org/10.3390/cancers13143425